NEWS

A Deal for Coronavirus Fiscal Relief

A Deal for Coronavirus Fiscal Relief

We recently had the honor of testifying before the House Ways and Means Committee on the effects of inaction on coronavirus fiscal legislation. One of us was invited by the Republicans and the other by the Democrats. The basis of the hearing was the Heroes Act, a $3 trillion bill that passed the House in the spring on a party line vote with about $1 trillion in tax cuts and $2 trillion in new spending.

read more
Demand for FDA Action Amid Shuffle

Demand for FDA Action Amid Shuffle

“That’s an impossible bar to clear, writes Alex Brill, an economist with Matrix Global Advisors and a fellow at the American Enterprise Institute, in a new report sponsored by the PBM lobby Pharmaceutical Care Management Association.”

read more
COVID-19 and Nursing Homes: National Updates and Early Evidence on the Second Wave

COVID-19 and Nursing Homes: National Updates and Early Evidence on the Second Wave

Evidence from the initial coronavirus outbreaks within the United States has shown that the fate of nursing home residents is tightly linked to the severity of the virus within the nursing home’s state. With a “second wave” of COVID-19 in many southern states and a host of policy changes, it is worth investigating whether the evidence suggests this vulnerable group is now better protected.

read more
Toward a Better Employee Retention Tax Credit

Toward a Better Employee Retention Tax Credit

Lawmakers in both chambers of Congress have staked out positions on expanding the Employee Retention Tax Credit (ERTC), a refundable tax credit that provides temporary wage support to help employers retain or rehire workers.

read more
A Tax Incentive, Not a Spending Program, to Boost Employment

A Tax Incentive, Not a Spending Program, to Boost Employment

Congress faces several critical choices before departing for their August recess. Should the $600-per-week additional unemployment insurance (UI) benefit (which has resulted in five of six workers earning more in unemployment benefits than wages) be extended, modified, or allowed to expire at the end of July?

read more
House Committee Calls for CMS Action on Biosimilars

House Committee Calls for CMS Action on Biosimilars

“‘One of the ways to align these incentives would be for CMS, in particular the Center for Medicare & Medicaid Innovation, to launch a demonstration project, a shared savings program in Medicare Part B for biosimilars. This would reward physicians for increasing their utilization of biosimilars, which would both create that incentive for physicians and align that incentive with the desire of taxpayers to lower overall costs in the biologic spend category,’ [Alex Brill] said.”

read more
The Evolving Opioid Crisis

The Evolving Opioid Crisis

As the COVID-19 pandemic has swept across our country and claimed more than 100,000 lives in a few short months, the opioid epidemic, which dates back to at least the early 2000s, has received less attention. But the toll of the opioid crisis in the United States remains enormous by any measure.

read more
The Economic Cost and Spatial Diffusion of the Opioid Crisis, 2009–18

The Economic Cost and Spatial Diffusion of the Opioid Crisis, 2009–18

Recent data show a small decline in opioid-related mortality following a decade during which opioid-related mortality more than doubled to nearly 53,000 in 2018. However, the aggregate statistics mask important spatial and temporal trends in the data. This report estimates nationwide, regional, and county-level economic costs associated with the opioid crisis.

read more

Have a Question?

Get In Touch

Get Our latest news

subscribe

Address

1350 Connecticut Avenue NW
Suite 610
Washington, DC 20036

Follow Us